title: Endothelial function markers in parkinsonian patients with hyperhomocysteinemia.
abstract: Hyperhomocysteinemia is considered a risk factor for vascular disease causing endothelial damage and consequently atherogenesis. The purpose of this study was to investigate the effect of elevated homocysteine on certain biochemical markers of endothelial function in patients with idiopathic Parkinson's disease (PD). Blood homocysteine levels were assessed in 57 PD patients and 40 matched normal controls. Investigation of the C677T 5,10 methylenetetrahydrofolate reductase (MTHFR) genotype was also performed in 43 PD patients. The following markers of endothelial function were assessed: superoxide dismutase (SOD), nitric oxide (NO), sICAM-1 and sE-selectin. Homocysteine levels were found mildly elevated in PD patients particularly in those treated with L-Dopa. MTHFR genotype did not influence significantly this finding. SOD activity was found reduced but it was not correlated to homocysteine levels. All other parameters measured were normal and were not related to hyperhomocysteinemia. Our findings indicate that mild hyperhomocysteinemia in PD patients was not associated with endothelial dysfunction.
authors.affiliation: 3rd University Dept. of Neurology, Thessaloniki, Greece. bostkamb@spark.net.gr
authors.forename: Sevasti
authors.initials: S
authors.lastname: Bostantjopoulou
authors.forename: Zoe
authors.initials: Z
authors.lastname: Katsarou
authors.forename: Theodora
authors.initials: T
authors.lastname: Frangia
authors.forename: Olga
authors.initials: O
authors.lastname: Hatzizisi
authors.forename: Kostas
authors.initials: K
authors.lastname: Papazisis
authors.forename: George
authors.initials: G
authors.lastname: Kyriazis
authors.forename: Gregory
authors.initials: G
authors.lastname: Kiosseoglou
authors.forename: Aristidis
authors.initials: A
authors.lastname: Kazis
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000978:Antiparkinson Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D016022:Case-Control Studies; D019040:E-Selectin / Q000378:metabolism; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005215:Fasting / Q000097:blood; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism*; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D010300:Parkinson Disease / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism*; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D000978:Antiparkinson Agents; D015415:Biomarkers; D019040:E-Selectin; D006710:Homocysteine; D018799:Intercellular Adhesion Molecule-1; D009569:Nitric Oxide; D007980:Levodopa; D013482:Superoxide Dismutase